, Tracking Stock Market Picks
Enter Symbol:
Ani Pharmaceuticals Inc. (ANIP) [hlAlert]

down 31.66 %

Ani Pharmaceuticals Inc. (ANIP) rated Outperform with price target $67 by Oppenheimer

Posted on: Tuesday,  Jun 23, 2015  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Ani Pharmaceuticals Inc. (NASDAQ: ANIP) on 06/23/2015. Previously Oppenheimer rated Outperform Ani Pharmaceuticals Inc. (NASDAQ: ANIP) on 10/15/2009.,
when the stock price was $70.20. Since then, Ani Pharmaceuticals Inc. has lost 31.67% as of 01/05/2016's recent price of $47.97.
If you would have followed the previous Oppenheimer's recommendation on ANIP, you would have lost 31.66% of your investment in 2273 days.

Biosante Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery. The Company?s principal products include LibiGel, Bio-T-Gel and Pill-Plus. The Company?s CaP products in development include BioLook, BioVant, BioOral and BioAir. In October 2009, BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. announced the completion of the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc., with BioSante Pharmaceuticals, Inc. as the surviving company. Pursuant to the merger, BioSante Pharmaceuticals, Inc. has acquired all of the outstanding shares of Cell Genesys, Inc.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/23/2015 8:25 AM Buy
62.35 67.00
as of 8/27/2015
1 Week down  -8.87 %
1 Month down  -22.04 %
3 Months down  -3.99 %
1 YTD up  146.56 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2014 9:25 AM Buy
35.15 40.00
2/19/2014 9:25 AM Buy
26.81 31.00
10/15/2009 8:25 AM Buy
70.20 216.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy